
    
      Adult patients at high risk for developing OM receiving one of the following myeloablative
      (MA) pre-transplant conditioning regimens prior to allogeneic transplant along with
      methotrexate (MTX) as part of graft vs. host disease (GVHD) prophylaxis meeting all other
      eligibility criteria will be enrolled:

        -  FluBu based regimens: either fludarabine: 30 mg/m^2 x 4 days and busulfan 0.8 mg/kg IV
           q6h x 4 days; both given daily starting at day -4 OR fludarabine: 40 mg/m^2 and
           busulfan: 3.2 mg/kg both given daily on days -6 through -3.

        -  Bu/Cy: busulfan, 0.8 mg/kg IV q6h x 4 days (-7 through -4); cyclophosphamide: 60 mg/kg
           IV once on days -3 and -2

        -  Cy/TBI: Cyclophosphamide, 60 mg/kg IV given twice between days -3 and -1 and TBI
           fractionated (generally over 3 days) for a total of 12Gy

      GVHD Prophylaxis:

      â€¢ Regimens including methotrexate (MTX; 15 mg/m^2 planned to be given on days 1, 3, 6 and
      11); addition of other agents given along with MTX (e.g., tacrolimus, sirolimus) is
      acceptable.

      Duration of treatment:

        -  Arm 1: GEL treatment a minimum of 4x/day initiated from 1st day of conditioning through
           OM resolution (G0), up to a maximum of 20d.

        -  Arms 2 (GEL) and 3 (MMW): Treatment a minimum of 4x/day initiated when G1 or G2 OM
           diagnosed during observation period (through Day +14 relative to stem cell infusion)
           through OM resolution (G0), up to a maximum of 20d.
    
  